Munich, Germany, February 28, 2014 – Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.

“We are pleased to receive the marketing authorization in South Korea for AirFluSal® Forspiro®. This is our first approval in Asia and outside Europe and a milestone in …